Inlyta Adverse Event Report 2018


This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions


Inlyta (axitinib) is a prescription medicine that interferes with the growth of some cancer cells. Inlyta is used to treat advanced kidney cancer (advanced renal cell carcinoma) when one prior drug treatment regimen for the kidney cancer has not worked. It is not known if Inlyta is safe and effective in children.